Ultimovacs ASA (ULTI.OL)

NOK 2.05

(0.0%)

Operating Expenses Summary of Ultimovacs ASA

Ultimovacs ASA's latest annual operating expenses in 2023 was 215.73 Million NOK , up 17.48% from previous year.
Ultimovacs ASA's latest quarterly operating expenses in 2024 Q2 was 45.12 Million NOK , up 61.55% from previous quarter.
Ultimovacs ASA reported a annual operating expenses of 183.63 Million NOK in annual operating expenses 2022, up 12.08% from previous year.
Ultimovacs ASA reported a annual operating expenses of 163.83 Million NOK in annual operating expenses 2021, up 31.97% from previous year.
Ultimovacs ASA reported a quarterly operating expenses of 45.12 Million NOK for 2024 Q2, up 61.55% from previous quarter.
Ultimovacs ASA reported a quarterly operating expenses of 50.76 Million NOK for 2023 Q1, down -29.74% from previous quarter.

Annual Operating Expenses Chart of Ultimovacs ASA (2023 - 2016)

Historical Annual Operating Expenses of Ultimovacs ASA (2023 - 2016)

Year	Operating Expenses	Operating Expenses Growth
2023	215.73 Million NOK	17.48%
2022	183.63 Million NOK	12.08%
2021	163.83 Million NOK	31.97%
2020	124.14 Million NOK	87.48%
2019	66.21 Million NOK	17.15%
2018	56.52 Million NOK	69.28%
2017	33.39 Million NOK	14.42%
2016	29.18 Million NOK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	27.93 Million NOK	-58.31%
2024 Q2	45.12 Million NOK	61.55%
2023 Q1	50.76 Million NOK	-29.74%
2023 Q4	67 Million NOK	22.49%
2023 Q3	54.7 Million NOK	8.03%
2023 Q2	50.64 Million NOK	-0.24%
2023 FY	223.17 Million NOK	21.53%
2022 Q2	35.42 Million NOK	11.04%
2022 Q1	31.9 Million NOK	-37.37%
2022 FY	183.63 Million NOK	12.08%
2022 Q4	72.25 Million NOK	64.01%
2022 Q3	44.05 Million NOK	24.37%
2021 Q1	31.21 Million NOK	22.0%
2021 FY	163.83 Million NOK	31.97%
2021 Q4	50.93 Million NOK	19.79%
2021 Q2	39.17 Million NOK	25.48%
2021 Q3	42.51 Million NOK	8.54%
2020 Q4	25.58 Million NOK	-17.77%
2020 Q1	31.25 Million NOK	12.31%
2020 Q2	36.18 Million NOK	15.75%
2020 Q3	31.11 Million NOK	-14.0%
2020 FY	124.14 Million NOK	87.48%
2019 Q1	14.97 Million NOK	11.19%
2019 FY	66.21 Million NOK	17.15%
2019 Q4	27.83 Million NOK	44.08%
2019 Q3	19.31 Million NOK	371.63%
2019 Q2	4.09 Million NOK	-72.64%
2018 Q1	10.96 Million NOK	39.06%
2018 FY	56.52 Million NOK	69.28%
2018 Q4	13.46 Million NOK	-21.65%
2018 Q3	17.18 Million NOK	15.27%
2018 Q2	14.9 Million NOK	35.92%
2017 Q1	8.8 Million NOK	0.0%
2017 Q2	8.21 Million NOK	-6.66%
2017 Q4	7.88 Million NOK	-7.0%
2017 Q3	8.48 Million NOK	3.19%
2017 FY	33.39 Million NOK	14.42%
2016 FY	29.18 Million NOK	0.0%

Peer Operating Expenses Comparison of Ultimovacs ASA

Name	Operating Expenses	Operating Expenses Difference
Arctic Bioscience AS	-5730.00 NOK	3765126.178%
Aqua Bio Technology ASA	18.46 Million NOK	-1068.346%
ArcticZymes Technologies ASA	97.26 Million NOK	-121.798%
BerGenBio ASA	192.17 Million NOK	-12.261%
Hofseth BioCare ASA	156.04 Million NOK	-38.254%
PCI Biotech Holding ASA	25.23 Million NOK	-755.043%
Thor Medical ASA	7.16 Million NOK	-2912.652%